Carlo Rizzuto (@carlo_rizzuto) 's Twitter Profile
Carlo Rizzuto

@carlo_rizzuto

ID: 4808804606

calendar_today24-01-2016 18:51:15

31 Tweet

179 Followers

275 Following

Carlo Rizzuto (@carlo_rizzuto) 's Twitter Profile Photo
Carlo Rizzuto
@carlo_rizzuto

6 years ago

Great couple of weeks for NYC biotech: -Quentis + Kallyope Fierce 15 2018 -Rgenix raises $40M ser C -Alexandria buys 175k sqft LIC site -Gotham launches with $54M ser A Congrats to all!

century_tx (@century_tx) 's Twitter Profile Photo
century_tx
@century_tx

5 years ago

Century Therapeutics Launches with $250M Financing for #iPSC-Based #Allogeneic Cell Therapy Platform bwnews.pr/2xmreIf #CellTherapy

Carlo Rizzuto (@carlo_rizzuto) 's Twitter Profile Photo
Carlo Rizzuto
@carlo_rizzuto

5 years ago

Congrats to the Pandion and Astellas teams!

century_tx (@century_tx) 's Twitter Profile Photo
century_tx
@century_tx

4 years ago

Today we announced the completion of a $160 million Series C financing. With these contributions by leading healthcare investors, we are well capitalized to advance our growing pipeline of #iPSC-derived cell therapies. Read more: bit.ly/3sLFCo0 #biotech #celltherapies

Today we announced the completion of a $160 million Series C financing. With these contributions by leading healthcare investors, we are well capitalized to advance our growing pipeline of #iPSC-derived cell therapies. Read more: bit.ly/3sLFCo0 #biotech #celltherapies
Carlo Rizzuto (@carlo_rizzuto) 's Twitter Profile Photo
Carlo Rizzuto
@carlo_rizzuto

3 years ago

Stablix Therapeutics Launches with $63 Million Series A Financing | Business Wire businesswire.com/news/home/2021…

century_tx (@century_tx) 's Twitter Profile Photo
century_tx
@century_tx

3 years ago

Our collaboration with Bristol Myers Squibb joins our industry leading iPSC-derived cell therapy platform with BMS’s expertise in cell therapy, hematology & oncology drug development to tackle challenging heme malignancies and solid tumors. $IPSC bit.ly/3fa3Wvg